Last reviewed · How we verify
NCT06091020: PaiNT
A Clinical Trial to Investigate Efficacy and Safety of NT 201 Injections Compared With Placebo Injections in Participants Aged 18 Years and Older With Chronic Nerve Pain After Shingles or Nerve Injury
Phase 2 trial testing IncobotulinumtoxinA in Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury in 123 participants. Completed in 4 July 2025.
7 May 2025
Quick facts
| Lead sponsor | Merz Therapeutics GmbH |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 123 |
| Start date | 22 November 2023 |
| Primary completion | 7 May 2025 |
| Estimated completion | 4 July 2025 |
| Sites | 31 locations across France, Germany, Poland, Hungary, Bulgaria, Spain |
Drugs / interventions tested
- IncobotulinumtoxinA (INCOBOTULINUMTOXINA) — full drug profile →
- Placebo
Conditions studied
- Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury — all drugs for Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury →
Sponsor
Merz Therapeutics GmbH — full company profile →
Who can join
18 and older, any sex, with Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this clinical trial, participants with nerve pain after shingles or nerve injury will receive injections with NT 201 or placebo. The purpose is to measure the decrease of nerve pain with NT 201 compared to placebo. Trial details include: * Trial duration: 22-23 weeks; * Treatment duration: 1 injection visit with a 20-week follow-up period; * Visit frequency: 2 remote visits by phone/video call (1 week and 12 weeks after the injection); 2 on-site visits (6 weeks and 20 weeks after the injection).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06091020
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IncobotulinumtoxinA
Trials testing the same drug.
- NCT06604832 — Effects of Microtox on Facial Skin Quality, Fine Wrinkles, and Texture · Phase 1 · completed
- NCT05222607 — Longitudinal Evaluation and Real-world Evidence of NT201 · terminated
- NCT05585398 — A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Di · Phase 1 · completed
- NCT04290169 — Effect of Video Game-assisted and BoNT-A Injection Therapy on Spasticity, Activity and Participation in CP Patients · NA · unknown
- NCT03044080 — Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot · Phase 4 · completed
Other Merz Therapeutics GmbH trials
Trials by the same sponsor.
- NCT06381999 — Validity and Inter-rater Reliability for Early Recognition of Spasticity Using the Decision Tree Tool · completed
- NCT05884528 — Assessment of Long-term Clinical Response to BoNT in Cervical Dystonia · completed
- NCT05943860 — Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06091020 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Merz Therapeutics GmbH
- Last refreshed: 24 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06091020.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing